Expert Insights On Decentralized Trials

  1. Where Do We Stand With DCTs Heading Into 2025? 12/9/2024

    Clinical Leader asked familiar voices and new faces alike: “What’s left to say, to understand, or to do with DCTs (or elements thereof) in 2025?”

  2. What's Trending In Medical Devices And Diagnostics For 2025? 12/4/2024

    Four program directors from the Medical Device Innovation Consortium (MDIC) share their predictions on the trends that will drive innovation and reshape clinical research in 2025.

  3. Semantics Matter: DCTs And An Industry Decentralized 6/4/2024

    Has the term "DCT" fallen out of favor? And if it has — especially among sites — what should take its place? Daniel J. Fox, MPH, Ph.D., clinical site advocate and entrepreneur, advocates for a more accurate and equitable moniker: DCV.

  4. Will Today's Clinical Trial Trends Become Tomorrow's Routine? 4/23/2024

    Clinical trial trends can be divided into two groups — those related to changes in the conduct of clinical trials and those related to the changes in therapeutic areas. Will these trends hold steady as 2024 unfolds?

  5. The Rise, Fall, And Eventual Rebound Of DCTs 3/25/2024

    First there was skepticism, then enthusiasm, and then disillusionment. DCTs have had their ups and downs. Here, we're looking ahead to the future of DCTs.

  6. Post-Pandemic Planning: Using Direct-To-Patient Deliveries For Supply Chain Management 2/23/2024

    UCB Vice President – Head of Global Clinical Science and Operations Tero Laulajainen gets us up to speed on direct-to-patient (DTP) trials and how UCB is leveraging it today.

  7. 4 Things I Learned At SCOPE 2024 2/21/2024

    The Summit for Clinical Ops Executives (SCOPE) ran from Feb. 11-4. Discover four things Executive Editor Abby Proch learned at the annual event.

  8. 4 Things I'm Looking Forward To At SCOPE 2024 2/1/2024

    The Summit for Clinical Ops Executives (SCOPE) begins Feb. 11. Discover four things Executive Editor Abby Proch is looking forward to at the annual event.

  9. 3 Ways Biotechs Can Lower The Cost Of Clinical Trials 1/23/2024

    LongeVC has identified three innovative models to help biotechs lower the cost of their clinical trials.

  10. The 3 Big Downsides To DCTs 1/8/2024

    James Gillespie, Ph.D., and Gregory Privitera, Ph.D. discuss three overlapping categories of concern when it comes to DCTs: consent and selection, user experience, and comfort and privacy.